Cargando…
PB2353: PROGNOSTIC VALUE OF TIME FROM SYMPTOMS BEGIN TO START TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA
Autores principales: | Lakhwani, Sunil Lakhwani, Santana, Ignacio Artiles, Pérez-Pinilla, Belén, Garcia, Alvaro Bienert, Saavedra, Minerva Montalvo, Díaz-Lopez, Marta, De Bonis-Braun, Carolina, Salazar, María José Rodríguez, Machado-Machado, Patricia, Garcia, Miguel Teodoro Hernandez, Raya, Jose Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429374/ http://dx.doi.org/10.1097/01.HS9.0000976128.37753.23 |
Ejemplares similares
-
PB2323: R-ESHAP VS R-ICE AS RESCUE TREATMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE-CENTEREXPERIENCE.
por: Pérez-Pinilla, Belén, et al.
Publicado: (2023) -
PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023) -
PB2210: COMPARISON OF THREE PROGNOSTIC SCORING SYSTEMS FOR THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA: ANALYSIS OF 190 PATIENTS AT THE UNIVERSITY HOSPITAL OF THE CANARY ISLANDS (1990-2022)
por: Raya, Jose Maria, et al.
Publicado: (2023) -
PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS
por: Allan, J. N., et al.
Publicado: (2022) -
Intramuscular Anti‐D treatment for immune thrombocytopenia: A single centre experience
por: Lakhwani, Sunil, et al.
Publicado: (2022)